ClinicalTrials.gg
CompletedNCT02226003Updated Sep 13, 2018Results posted

Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)

A Phase 3 interventional study of Ertugliflozin and Sitagliptin in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
291
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.

Enrollment
11th of 28
291 · median 83
Started
2014
with 3 others
Phase 3
11 of 28
none open now
Registered
16th of 28
by date
Lead sponsor
18 of 28
Merck Sharp & Dohme LLC

Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 4 that started in 2014, is one of 11 in phase 3, and was the 16th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ertugliflozin

ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a study to evaluate the efficacy and safety of ertugliflozin (MK-8835/PF-04971729) in combination with sitagliptin in the treatment of participants with Type 2 diabetes mellitus (T2DM) with inadequate glycemic control on diet and exercise. The primary hypothesis of the study is that ertugliflozin plus sitagliptin is more effective in lowering of hemoglobin A1C (HbA1C) than placebo.

Read the detailed description

Each participant will be in the study for approximately 39 weeks including: a 1-week screening period, an 8-week (or greater) antihyperglycemic agent (AHA) wash-off period, a 2-week single-blind placebo run-in period, a 26-week double-blind treatment period, and a post-treatment telephone contact 14 days after the last dose of study drug.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus as per American Diabetes Association guidelines
  • Not on antihyperglycemic agent (AHA) >=8 weeks with a Visit 1/Screening >=8.0% and \<=10.5% (>=64 mmol/mol and \<=91 mmol/mol) OR on single allowable AHA (allowable AHAs prior to screening are: metformin, α-glucosidase inhibitors, sulfonylureas and glinides) with a Visit 1/Screening HbA1C >=7.5% and \<=10.0% (>=58 mmol/mol and \<=86 mmol/mol) OR on low-dose dual combination therapy (≤50% of maximum labeled dose of an AHA) with allowable AHAs with a Visit 1/Screening HbA1C >=7.5% and \<=10.0% (>=58 mmol/mol and \<=86 mmol/mol)
  • (BMI) >=18.0 kg/m\^2
  • Male or female not of
  • Female of reproductive potential who agrees to (or have their partner agree to) remain abstinent from heterosexual activity or to use 2 acceptable combinations of .

Exclusion criteria

Exclusion Criteria:

  • History of type 1 diabetes mellitus or diabetic ketoacidosis
  • History of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant
  • A known or intolerance to any sodium glucose co-transporter (SGLT2) inhibitor or sitagliptin
  • Has been treated with any of the following agents within 12 weeks of study start or during the pre-randomization period: insulin of any type (except for short-term use [i.e., \<=7 days] during concomitant illness or other stress), other injectable anti-hyperglycemic agents (e.g., pramlintide, exenatide, liraglutide), pioglitazone or rosiglitazone, other sodium glucose co-transporter 2 (SGLT2) inhibitors, dipeptidyl-peptidase 4 inhibitors (DPP-4 inhibitors), bromocriptine (Cycloset™), colesevelam (Welchol™), any other AHA with the exception of the protocol-approved agents
  • Is on a weight-loss program or weight-loss medication or other medication associated with weight changes and is not weight stable prior to study start
  • Has undergone bariatric surgery within the past 12 months or >12 months and is not weight stable prior to study start
  • A history of myocardial infarction, unstable angina, arterial revascularization, stroke, , or (NYHA) functional Class III-IV heart failure within 3 months of study start
  • Active, obstructive uropathy or indwelling urinary catheter
  • History of \<=5 years prior to study start, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
  • A known history of (HIV)
  • A blood dyscrasia or any disorder causing hemolysis or unstable red blood cells, or a hematological disorder (e.g. aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)
  • A medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active or C, primary biliary cirrhosis, or symptomatic gallbladder disease
  • Any clinically significant malabsorption condition
  • Current treatment for hyperthyroidism
  • On thyroid replacement therapy and not on a stable dose for at least 6 weeks prior study start
  • On a previous clinical study with ertugliflozin
  • Participated in other studies involving drug(s) 30 days prior to study start
  • Surgical procedure within 6 weeks prior to study start or major surgery planned during the trial
  • Positive urine pregnancy test
  • Pregnant or breast-feeding, or planning to conceive during the trial, including 14 days following the last dose of study medication
  • Planning to undergo hormonal therapy in preparation for egg donation during the trial, including 14 days following the last dose of study medication
  • Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week or engages in binge drinking
  • Donated blood or blood products within 6 weeks of study start.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
291 participants (actual)

Study arms

  • Experimental
    Ertugliflozin 5 mg and Sitagliptin 100 mg

    Ertugliflozin, 5 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks. Placebo to ertugliflozin, 10 mg, administered orally, once daily for 26 weeks.

    Drug: Ertugliflozin · Drug: Sitagliptin · Drug: Placebo to Ertugliflozin · Drug: Glimepiride

  • Experimental
    Ertugliflozin 15 mg and Sitagliptin 100 mg

    Ertugliflozin, 15 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.

    Drug: Ertugliflozin · Drug: Sitagliptin · Drug: Glimepiride

  • Placebo comparator
    Placebo to Ertugliflozin and Placebo to Sitagliptin

    Placebo to ertugliflozin, 5 mg and 10 mg, administered orally, once daily for 26 weeks. Placebo to sitagliptin, 100 mg, administered orally, once daily for 26 weeks.

    Drug: Placebo to Ertugliflozin · Drug: Placebo to Sitagliptin · Drug: Glimepiride

Interventions

  • Ertugliflozin, 5 mg or 15 mg, administered orally, once daily for 26 weeks.

  • Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.

  • DrugPlacebo to Ertugliflozin

    Matching placebo to ertugliflozin administered orally, once daily for 26 weeks.

  • DrugPlacebo to Sitagliptin

    Matching placebo to sitagliptin administered orally, once daily for 26 weeks.

  • Open-label glimepiride rescue therapy will be initiated at 1 or 2 mg/day and may be titrated to the maximum labeled dose or maximum tolerated dose (if lower than labeled dose), as considered appropriate by the investigator, based on blood glucose measurements and in accordance with the local, approved label.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1C (HbA1C) at Week 26 - Full Analysis Set (FAS Population Excluding Rescue Approach

    HbA1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). HbA1C represents the percentage of glycated hemoglobin. A negative number indicates a reduction in HbA1C level. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride.

    Time frame: Baseline and Week 26

  2. Percentage of Participants Who Experienced an Adverse Event (AE) - All Participants as Treated Excluding Rescue Approach

    An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride.

    Time frame: Up to Week 28

  3. Percentage of Participants Who Discontinued Study Medication Due to an AE - All Participants as Treated Excluding Rescue Approach

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride.

    Time frame: Up to Week 26

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Full Analysis Set Excluding Rescue Approach

    Blood glucose was measured after a ≥10 hour fast. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at baseline). Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride.

    Time frame: Baseline and Week 26

  2. Change From Baseline in 2-hour Post-Meal Glucose (PMG) at Week 26 - Full Analysis Set Excluding Rescue Approach

    Change from baseline at Week 26 is defined as 2-hour PMG at Week 26 minus 2-hour PMG at Week 0. Two-hour post-meal glucose was measured following a standard meal. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride.

    Time frame: Baseline and Week 26

  3. Percentage of Participants With HbA1C <7% (<53 mmol/Mol) at Week 26

    HbA1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). HbA1c represents the percentage of glycated hemoglobin.

    Time frame: Week 26

  4. Change From Baseline in Body Weight at Week 26 - Full Analysis Set Excluding Rescue Approach

    Body weight was measured using a standardized, digital scale at each of the pre-defined nominal time points. Weight was taken in duplicate throughout the trial at approximately the same time of day, after voiding (i.e., forced void) and while wearing only a gown and underwear. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride.

    Time frame: Baseline and Week 26

  5. Change From Baseline in Sitting Systolic Blood Pressure at Week 26 - Full Analysis Set Excluding Rescue Approach

    Blood pressure measurements were taken after at least 5 minutes of rest. Three measurements were taken approximately 2 minutes apart with the triplicate set recorded. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride.

    Time frame: Baseline and Week 26

  6. Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 - Full Analysis Set Excluding Rescue Approach

    Blood pressure measurements were taken after at least 5 minutes of rest. Three measurements were taken approximately 2 minutes apart with the triplicate set recorded. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride.

    Time frame: Baseline and Week 26

07

Results

Posted Apr 7, 2017

Participant flow

A total of 96 sites received independent ethics committees/institutional review boards' approval and 66 sites in 9 countries enrolled at least 1 participant.

Participant flow — Overall Study
MilestoneErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgPlacebo
Started989697
Completed969591
Not completed216
Withdrew: Lost to follow-up213
Withdrew: Withdrawal by subject003

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1C (HbA1C) at Week 26 - Full Analysis Set (FAS Population Excluding Rescue Approach

HbA1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). HbA1C represents the percentage of glycated hemoglobin. A negative number indicates a reduction in HbA1C level. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Percentage
Change From Baseline in Hemoglobin A1C (HbA1C) at Week 26 - Full Analysis Set (FAS Population Excluding Rescue Approach
PercentageErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgPlacebo
Change From Baseline in Hemoglobin A1C (HbA1C) at Week 26 - Full Analysis Set (FAS Population Excluding Rescue Approach-1.60 (-1.82 to -1.39)-1.68 (-1.90 to -1.46)-0.44 (-0.69 to -0.19)
Statistical analysis
  • Ertugliflozin 5 mg + Sitagliptin 100 mg vs Placebo · Constrained Longitudinal Data Analysis · p = < 0.001 · Difference in the least squares means: -1.16 · 95% CI -1.49 to -0.84
  • Ertugliflozin 15 mg + Sitagliptin 100 mg vs Placebo · Constrained Longitudinal Data Analysis · p = < 0.001 · Difference in the least squares means: -1.24 · 95% CI -1.57 to -0.91
PrimaryPercentage of Participants Who Experienced an Adverse Event (AE) - All Participants as Treated Excluding Rescue Approach

An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride.

Time frame:
Up to Week 28
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experienced an Adverse Event (AE) - All Participants as Treated Excluding Rescue Approach
Percentage of ParticipantsErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgPlacebo
Percentage of Participants Who Experienced an Adverse Event (AE) - All Participants as Treated Excluding Rescue Approach44.944.842.3
Statistical analysis
  • Ertugliflozin 5 mg + Sitagliptin 100 mg vs Placebo · Difference in percentage vs placebo: 2.6 · 95% CI -11.2 to 16.4
  • Ertugliflozin 15 mg + Sitagliptin 100 mg vs Placebo · Difference in percentage vs placebo: 2.5 · 95% CI -11.4 to 16.4
PrimaryPercentage of Participants Who Discontinued Study Medication Due to an AE - All Participants as Treated Excluding Rescue Approach

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride.

Time frame:
Up to Week 26
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Discontinued Study Medication Due to an AE - All Participants as Treated Excluding Rescue Approach
Percentage of ParticipantsErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgPlacebo
Percentage of Participants Who Discontinued Study Medication Due to an AE - All Participants as Treated Excluding Rescue Approach2.02.12.1
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Full Analysis Set Excluding Rescue Approach

Blood glucose was measured after a ≥10 hour fast. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at baseline). Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · milligrams/deciliter
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Full Analysis Set Excluding Rescue Approach
milligrams/deciliterErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgPlacebo
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Full Analysis Set Excluding Rescue Approach-48.25 (-56.12 to -40.38)-55.36 (-63.29 to -47.42)-9.30 (-18.58 to -0.02)
Statistical analysis
  • Ertugliflozin 5 mg + Sitagliptin 100 mg vs Placebo · Constrained Longitudinal Data Analysis · p = < 0.001 · Difference in the least squares means: -38.94 · 95% CI -49.93 to -27.96
  • Ertugliflozin 15 mg + Sitagliptin 100 mg vs Placebo · Constrained Longitudinal Data Analysis · p = < 0.001 · Difference in the least squares means: -46.05 · 95% CI -57.09 to -35.02
SecondaryChange From Baseline in 2-hour Post-Meal Glucose (PMG) at Week 26 - Full Analysis Set Excluding Rescue Approach

Change from baseline at Week 26 is defined as 2-hour PMG at Week 26 minus 2-hour PMG at Week 0. Two-hour post-meal glucose was measured following a standard meal. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · milligrams/deciliter
Change From Baseline in 2-hour Post-Meal Glucose (PMG) at Week 26 - Full Analysis Set Excluding Rescue Approach
milligrams/deciliterErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgPlacebo
Change From Baseline in 2-hour Post-Meal Glucose (PMG) at Week 26 - Full Analysis Set Excluding Rescue Approach-82.80 (-95.96 to -69.64)-90.03 (-103.34 to -76.71)-20.38 (-35.62 to -5.14)
Statistical analysis
  • Ertugliflozin 5 mg + Sitagliptin 100 mg vs Placebo · Constrained Longitudinal Data Analysis · p = < 0.001 · Difference in the least squares means: -62.42 · 95% CI -80.47 to -44.37
  • Ertugliflozin 15 mg + Sitagliptin 100 mg vs Placebo · Constrained Longitudinal Data Analysis · p = < 0.001 · Difference in the least squares means: -69.65 · 95% CI -87.83 to -51.46
SecondaryPercentage of Participants With HbA1C <7% (<53 mmol/Mol) at Week 26

HbA1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). HbA1c represents the percentage of glycated hemoglobin.

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants With HbA1C <7% (<53 mmol/Mol) at Week 26
Percentage of participantsErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgPlacebo
Percentage of Participants With HbA1C <7% (<53 mmol/Mol) at Week 2635.731.38.3
Statistical analysis
  • Ertugliflozin 5 mg + Sitagliptin 100 mg vs Placebo · Logistic regression model · p = < 0.001 · Odds ratio (or): 6.88 · 95% CI 2.81 to 16.83
  • Ertugliflozin 15 mg + Sitagliptin 100 mg vs Placebo · Logistic regression model · p = < 0.001 · Odds ratio (or): 7.39 · 95% CI 2.98 to 18.31
SecondaryChange From Baseline in Body Weight at Week 26 - Full Analysis Set Excluding Rescue Approach

Body weight was measured using a standardized, digital scale at each of the pre-defined nominal time points. Weight was taken in duplicate throughout the trial at approximately the same time of day, after voiding (i.e., forced void) and while wearing only a gown and underwear. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Kilograms
Change From Baseline in Body Weight at Week 26 - Full Analysis Set Excluding Rescue Approach
KilogramsErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgPlacebo
Change From Baseline in Body Weight at Week 26 - Full Analysis Set Excluding Rescue Approach-2.94 (-3.60 to -2.28)-3.04 (-3.71 to -2.38)-0.94 (-1.70 to -0.18)
Statistical analysis
  • Ertugliflozin 5 mg + Sitagliptin 100 mg vs Placebo · Constrained Longitudinal Data Analysis · p = < 0.001 · Difference in the least squares means: -2.00 · 95% CI -2.99 to -1.01
  • Ertugliflozin 15 mg + Sitagliptin 100 mg vs Placebo · Constrained Longitudinal Data Analysis · p = < 0.001 · Difference in the least squares means: -2.10 · 95% CI -3.10 to -1.11
SecondaryChange From Baseline in Sitting Systolic Blood Pressure at Week 26 - Full Analysis Set Excluding Rescue Approach

Blood pressure measurements were taken after at least 5 minutes of rest. Three measurements were taken approximately 2 minutes apart with the triplicate set recorded. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · millimeters of mercury
Change From Baseline in Sitting Systolic Blood Pressure at Week 26 - Full Analysis Set Excluding Rescue Approach
millimeters of mercuryErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgPlacebo
Change From Baseline in Sitting Systolic Blood Pressure at Week 26 - Full Analysis Set Excluding Rescue Approach-2.04 (-4.23 to 0.16)-3.98 (-6.19 to -1.78)2.41 (-0.34 to 5.15)
Statistical analysis
  • Ertugliflozin 5 mg + Sitagliptin 100 mg vs Placebo · Constrained Longitudinal Data Analysis · p = 0.011 · Difference in the least squares means: -4.44 · 95% CI -7.87 to -1.01
  • Ertugliflozin 15 mg + Sitagliptin 100 mg vs Placebo · Constrained Longitudinal Data Analysis · p = < 0.001 · Difference in the least squares means: -6.39 · 95% CI -9.83 to -2.95
SecondaryChange From Baseline in Sitting Diastolic Blood Pressure at Week 26 - Full Analysis Set Excluding Rescue Approach

Blood pressure measurements were taken after at least 5 minutes of rest. Three measurements were taken approximately 2 minutes apart with the triplicate set recorded. Excluding rescue approach excludes all data following the initiation of rescue, in order to avoid the confounding influence of the rescue therapy with open-label glimepiride.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · millimeters of mercury
Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 - Full Analysis Set Excluding Rescue Approach
millimeters of mercuryErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgPlacebo
Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 - Full Analysis Set Excluding Rescue Approach-0.44 (-1.99 to 1.11)-0.97 (-2.52 to 0.59)1.21 (-0.73 to 3.15)
Statistical analysis
  • Ertugliflozin 5 mg + Sitagliptin 100 mg vs Placebo · Constrained Longitudinal Data Analysis · p = 0.184 · Difference in the least squares means: -1.65 · 95% CI -4.09 to 0.79
  • Ertugliflozin 15 mg + Sitagliptin 100 mg vs Placebo · Constrained Longitudinal Data Analysis · p = 0.080 · Difference in the least squares means: -2.18 · 95% CI -4.62 to 0.26

Adverse events

Collected over Up to Week 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ertugliflozin 5 mg + Sitagliptin 100 mg—2/98 (2%)8/98 (8.2%)
Ertugliflozin 15 mg + Sitagliptin 100 mg—3/96 (3.1%)3/96 (3.1%)
Placebo—5/97 (5.2%)12/97 (12.4%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgPlacebo
Urinary tract infectionInfections and infestations0/981/960/97
Endometrial adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/981/960/97
Allergy to arthropod stingImmune system disorders0/981/960/97
Ischaemic strokeNervous system disorders0/980/961/97
NephrolithiasisRenal and urinary disorders0/980/961/97
AngioedemaSkin and subcutaneous tissue disorders0/980/961/97
AppendicitisInfections and infestations0/980/961/97
Cellulitis staphylococcalInfections and infestations0/980/961/97
PeritonitisInfections and infestations0/980/961/97
Multiple fracturesInjury, poisoning and procedural complications0/980/961/97
Most frequent other events
Most frequent other events
EventErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgPlacebo
Blood glucose increasedInvestigations3/980/967/97
HyperglycaemiaMetabolism and nutrition disorders0/981/966/97
Urinary tract infectionInfections and infestations5/982/961/97

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ertugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgPlaceboTotal
Mean56.4 ± 9.356.1 ± 10.154.3 ± 10.355.6 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)Ertugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgPlaceboTotal
Female414340124
Male575357167
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Miller S, Krumins T, Zhou H, Huyck S, Johnson J, Golm G, Terra SG, Mancuso JP, Engel SS, Lauring B. Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study. Diabetes Ther. 2018 Feb;9(1):253-268. doi: 10.1007/s13300-017-0358-0. Epub 2018 Jan 8. PubMed 29313282 ↗
  • Gallo S, Raji A, Calle RA, Pong A, Meyer C. The effects of ertugliflozin on beta-cell function: Pooled analysis from four phase 3 randomized controlled studies. Diabetes Obes Metab. 2020 Dec;22(12):2267-2275. doi: 10.1111/dom.14149. Epub 2020 Aug 27. PubMed 32700393 ↗
  • Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Ther. 2020 Aug;11(8):1849-1860. doi: 10.1007/s13300-020-00867-1. Epub 2020 Jul 9. PubMed 32648108 ↗
  • Patel S, Hickman A, Frederich R, Johnson S, Huyck S, Mancuso JP, Gantz I, Terra SG. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Ther. 2020 Jun;11(6):1347-1367. doi: 10.1007/s13300-020-00803-3. Epub 2020 May 5. PubMed 32372382 ↗
  • Liu J, Tarasenko L, Pong A, Huyck S, Wu L, Patel S, Hickman A, Mancuso JP, Gantz I, Terra SG. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Aug;36(8):1277-1284. doi: 10.1080/03007995.2020.1760228. Epub 2020 May 13. PubMed 32324082 ↗
  • Liu J, Tarasenko L, Pong A, Huyck S, Patel S, Hickman A, Mancuso JP, Ellison MC, Gantz I, Terra SG. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Jul;36(7):1097-1106. doi: 10.1080/03007995.2020.1760227. Epub 2020 May 13. PubMed 32324065 ↗
  • Liu J, Patel S, Cater NB, Wu L, Huyck S, Terra SG, Hickman A, Darekar A, Pong A, Gantz I. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2020 Apr;22(4):574-582. doi: 10.1111/dom.13931. Epub 2020 Jan 3. PubMed 31797522 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Feb 2016, 17 months.

Results were first posted in Apr 2017, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 17 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2014
First posted
Aug 26, 2014
StartActual
Sep 23, 2014
Primary completionActual
Feb 23, 2016
CompletionActual
Feb 23, 2016
Results first posted
Apr 7, 2017
Last update
Sep 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02226003
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Aug 26, 2014
Start date
Sep 23, 2014
Primary completion
Feb 23, 2016
Completion
Feb 23, 2016
Results posted
Apr 7, 2017
Last update
Sep 13, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ertugliflozin

Start the discussion